133 related articles for article (PubMed ID: 29770447)
1. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Ahn H; Tay J; Shea B; Hutton B; Shorr R; Knoll GA; Cameron DW; Cowan J
Transfusion; 2018 Oct; 58(10):2437-2452. PubMed ID: 29770447
[TBL] [Abstract][Full Text] [Related]
2. Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation.
Cowan J; Cameron DW; Knoll G; Tay J
BMJ Open; 2015 Aug; 5(8):e008316. PubMed ID: 26297369
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
4. Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.
Beyar-Katz O; Bitterman R; Zuckerman T; Ofran Y; Yahav D; Paul M
Clin Microbiol Infect; 2020 Feb; 26(2):189-198. PubMed ID: 31536817
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Jones CA; Strippoli GF; Webster AC; Craig JC
Cochrane Database Syst Rev; 2007 Apr; (2):CD005129. PubMed ID: 17443573
[TBL] [Abstract][Full Text] [Related]
6. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.
Rowe RG; Guo D; Lee M; Margossian S; London WB; Lehmann L
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1275-1283. PubMed ID: 27090959
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation.
Raanani P; Gafter-Gvili A; Paul M; Ben-Bassat I; Leibovici L; Shpilberg O
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD006501. PubMed ID: 18843719
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.
Quellmann S; Schwarzer G; Hübel K; Greb A; Engert A; Bohlius J
Cochrane Database Syst Rev; 2008 Jul; (3):CD004885. PubMed ID: 18646116
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis.
Raanani P; Gafter-Gvili A; Paul M; Ben-Bassat I; Leibovici L; Shpilberg O
J Clin Oncol; 2009 Feb; 27(5):770-81. PubMed ID: 19114702
[TBL] [Abstract][Full Text] [Related]
12. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.
Theurich S; Fischmann H; Chakupurakal G; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Rothe A; Scheid C; Hallek M; Skoetz N; von Bergwelt-Baildon M
Crit Rev Oncol Hematol; 2013 Oct; 88(1):178-86. PubMed ID: 23561334
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.
Wang L; Gu Z; Zhai R; Li D; Zhao S; Luo L; Zhao X; Wei H; Pang Z; Wang L; Liu D; Wang Q; Gao C
Transfusion; 2015 Sep; 55(9):2134-41. PubMed ID: 25857725
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
[TBL] [Abstract][Full Text] [Related]
15. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial.
Cordonnier C; Chevret S; Legrand M; Rafi H; Dhédin N; Lehmann B; Bassompierre F; Gluckman E;
Ann Intern Med; 2003 Jul; 139(1):8-18. PubMed ID: 12834313
[TBL] [Abstract][Full Text] [Related]
16. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation.
Tay J; Tinmouth A; Fergusson D; Huebsch L; Allan DS
Biol Blood Marrow Transplant; 2007 Feb; 13(2):206-17. PubMed ID: 17241926
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones CJ; Craig JC
Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
